Related Experiment Video
Updated: Sep 3, 2025

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
TNK2/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of
Surbhi Chouhan1,2, Mithila Sawant1,2, Cody Weimholt3
1Department of Surgery, Cancer Research Building, St. Louis, MO, USA.
Abstract:
The challenge of rapid macromolecular synthesis enforces the energy-hungry cancer cell mitochondria to switch their metabolic phenotypes, accomplished by activation of oncogenic tyrosine kinases. Precisely how kinase activity is directly exploited by cancer cell mitochondria to meet high-energy demand, remains to be deciphered. Here we show that a non-receptor tyrosine kinase, TNK2/ACK1 (tyrosine kinase non receptor 2), phosphorylated ATP5F1A (ATP synthase F1 subunit alpha) at Tyr243 and Tyr246 (Tyr200 and 203 in the mature protein, respectively) that not only increased the stability of complex V, but also increased mitochondrial energy output in cancer cells. Further, phospho-ATP5F1A (p-Y-ATP5F1A) prevented its binding to its physiological inhibitor, ATP5IF1 (ATP synthase inhibitory factor subunit 1), causing sustained mitochondrial activity to promote cancer cell growth. TNK2 inhibitor, (R)-9b reversed this process and induced mitophagy-based autophagy to mitigate prostate tumor growth while sparing normal prostate cells. Further, depletion of p-Y-ATP5F1A was needed for (R)-9b-mediated mitophagic response and tumor growth. Moreover, Tnk2 transgenic mice displayed increased p-Y-ATP5F1A and loss of mitophagy and exhibited formation of prostatic intraepithelial neoplasia (PINs). Consistent with these data, a marked increase in p-Y-ATP5F1A was seen as prostate cancer progressed to the malignant stage. Overall, this study uncovered the molecular intricacy of tyrosine kinase-mediated mitochondrial energy regulation as a distinct cancer cell mitochondrial vulnerability and provided evidence that TNK2 inhibitors can act as "mitocans" to induce cancer-specific mitophagy.Abbreviations: ATP5F1A: ATP synthase F1 subunit alpha; ATP5IF1: ATP synthase inhibitory factor subunit 1; CRPC: castration-resistant prostate cancer; DNM1L: dynamin 1 like; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; Mdivi-1: mitochondrial division inhibitor 1; Mut-ATP5F1A: Y243,246A mutant of ATP5F1A; OXPHOS: oxidative phosphorylation; PC: prostate cancer; PINK1: PTEN induced kinase 1; p-Y-ATP5F1A: phosphorylated tyrosine 243 and 246 on ATP5F1A; TNK2/ACK1: tyrosine kinase non receptor 2; Ub: ubiquitin; WT: wild type.
Insights
Cancer cells exploit tyrosine kinase TNK2/ACK1 to boost mitochondrial energy production by phosphorylating ATP synthase. Inhibiting TNK2 triggers mitophagy, reducing tumor growth and offering a new cancer therapy strategy.
Area of Science:
- Biochemistry
- Cancer Biology
- Mitochondrial Metabolism
Background:
- Cancer cells require high energy due to rapid macromolecular synthesis, necessitating metabolic adaptations.
- Oncogenic tyrosine kinases are activated in cancer, but their direct role in meeting cancer cell mitochondrial energy demands is unclear.
- Mitochondrial function and metabolic reprogramming are critical for cancer cell survival and proliferation.
Purpose of the Study:
- To elucidate the mechanism by which tyrosine kinase activity directly enhances mitochondrial energy output in cancer cells.
- To investigate the role of TNK2/ACK1 in regulating ATP synthase stability and activity.
- To evaluate the therapeutic potential of targeting TNK2 for cancer treatment, specifically inducing mitophagy.
Main Methods:
- Phosphorylation analysis of ATP synthase F1 subunit alpha (ATP5F1A) by TNK2/ACK1.
- Assessment of Complex V stability and mitochondrial energy output in cancer cells.
- Treatment with a TNK2 inhibitor ((R)-9b) and evaluation of its effects on mitophagy, tumor growth, and p-Y-ATP5F1A levels.
- Analysis of Tnk2 transgenic mice and human prostate cancer progression.
Main Results:
- TNK2/ACK1 phosphorylates ATP5F1A at Tyr243 and Tyr246, increasing Complex V stability and mitochondrial energy output.
- Phospho-ATP5F1A (p-Y-ATP5F1A) inhibits binding to ATP5IF1, sustaining mitochondrial activity and promoting cancer growth.
- The TNK2 inhibitor (R)-9b reverses these effects, inducing mitophagy and reducing prostate tumor growth while sparing normal cells.
- Depletion of p-Y-ATP5F1A is essential for (R)-9b-mediated mitophagy and tumor suppression.
- Tnk2 overexpression in mice leads to increased p-Y-ATP5F1A, reduced mitophagy, and prostatic intraepithelial neoplasia (PINs).
- Elevated p-Y-ATP5F1A correlates with prostate cancer progression.
Conclusions:
- Tyrosine kinase-mediated regulation of mitochondrial energy production represents a vulnerability in cancer cells.
- TNK2/ACK1 plays a crucial role in enhancing mitochondrial ATP production through ATP5F1A phosphorylation.
- TNK2 inhibitors can function as 'mitocans,' selectively inducing mitophagy in cancer cells and offering a targeted therapeutic strategy.
More Related Videos
08:16Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
Published on: August 15, 2025
13:15Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
Published on: February 25, 2016
Related Concept Videos
ATP Synthase: Mechanism
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
ATP Synthase: Structure
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...